Pathologic Response Rates of GemcitabineCisplatin versus MethotrexateVinblastineAdriamycinCisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
Joint Authors
Wright, Jonathan L.
Izard, Jason
Wang, Junfeng
Yu, Evan Y.
Gore, John L.
Lee, Franklin C.
Cheng, Heather H.
Shenoi, Jaideep
Zhao, Song
Harris, William
Champion, Thomas
Porter, Michael P.
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-12-08
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Objectives.
To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting.
Methods.
Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical cystectomy between 2003 and 2011.
Outcomes of interest included those with complete response (pT0) and any response (≤pT1).
Odds ratios were calculated using multivariate logistic regression.
Results.
Compared to those who did not receive neoadjuvant chemotherapy, there were more patients with complete response (28% versus 9%, OR 3.11 (95% CI: 1.45–6.64), P=0.03) and any response (52% versus 25%, OR 3.23 (95% CI: 1.21–8.64), P=0.01).
Seventy-two patients received GC (n=41) or MVAC (n=31).
CR was achieved in 29% and 22% of GC and MVAC patients, respectively (multivariate OR 0.39, 95% CI 0.10–1.58).
Any response (≤pT1) was achieved in 56% of GC and 45% of MVAC patients (multivariate OR 0.45, 95% CI 0.12–1.71).
Conclusions.
We observed similar pathologic response rates for GC and MVAC neoadjuvant chemotherapy in this cohort of patients with muscle invasive urothelial cancer (MIBC).
Our findings support the use of GC as an alternative regimen in the neoadjuvant setting.
American Psychological Association (APA)
Lee, Franklin C.& Harris, William& Cheng, Heather H.& Shenoi, Jaideep& Zhao, Song& Wang, Junfeng…[et al.]. 2013. Pathologic Response Rates of GemcitabineCisplatin versus MethotrexateVinblastineAdriamycinCisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-462981
Modern Language Association (MLA)
Lee, Franklin C.…[et al.]. Pathologic Response Rates of GemcitabineCisplatin versus MethotrexateVinblastineAdriamycinCisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-462981
American Medical Association (AMA)
Lee, Franklin C.& Harris, William& Cheng, Heather H.& Shenoi, Jaideep& Zhao, Song& Wang, Junfeng…[et al.]. Pathologic Response Rates of GemcitabineCisplatin versus MethotrexateVinblastineAdriamycinCisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-462981
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-462981